Aton Pharma Moves Beyond Its Merck Connections With Pick-up From Bristol
This article was originally published in The Pink Sheet Daily
Executive Summary
Specialty pharma focuses on acquiring marketing rights to mature products underappreciated in their market areas.
You may also be interested in...
Valeant Pharmaceuticals To Buy Aton For $318 Mil.; Bolsters U.S. Specialty Business
Acquisition is expected to buffer sales that will be lost when Valeant's epilepsy drug Diastat faces generic competition later this year.
Valeant Pharmaceuticals To Buy Aton For $318 Mil.; Bolsters U.S. Specialty Business
Acquisition is expected to buffer sales that will be lost when Valeant's epilepsy drug Diastat faces generic competition later this year.
Deals Of The Week: Charles River/WuXi, Aton/Bristol, Merck/Nycomed ...
Each week, "The Pink Sheet" presents commentary on some of the week's most interesting business deals, contributed by the editors of the IN VIVO blog. Visit the blog at 1http://invivoblog.blogspot.com